Hermetica Superfood Encyclopedia
The Short Answer
Excavatolide B is a polyoxygenated diterpenoid (C₃₁H₄₄O₁₁, MW 592.6 g/mol) that suppresses inflammation by dose-dependently inhibiting iNOS and COX-2 mRNA and protein expression through NF-κB pathway downregulation in LPS-stimulated macrophages. Preclinical data demonstrate significant reduction in nitric oxide production and osteoclast differentiation markers at 1–50 μM in vitro, with anti-inflammatory and analgesic effects confirmed in carrageenan-induced animal models (p < 0.05 vs. controls), though no human clinical data exist.
CategoryCompound
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordexcavatolide B anti-inflammatory
Excavatolide B — botanical close-up
Health Benefits
**Anti-Inflammatory Activity**
Excavatolide B dose-dependently inhibits iNOS mRNA and protein expression at 1–50 μM and COX-2 mRNA at 25–50 μM in LPS-activated RAW 264.7 macrophages, significantly reducing the pro-inflammatory signaling cascade (p < 0.05 vs. LPS alone, n=6 per group).
**Nitric Oxide Suppression**
By inhibiting iNOS expression, excavatolide B reduces pathological nitric oxide production in activated macrophages, which in turn attenuates downstream COX-2 induction and inflammatory amplification through NF-κB transcriptional suppression.
**Anti-Osteoclast / Anti-Arthritic Effects**
At 10 μM, excavatolide B inhibits LPS-induced osteoclast differentiation by reducing multinucleated cell formation, actin ring assembly, and TRAP activity in preclinical bone cell models, suggesting potential relevance to inflammatory arthritis pathophysiology.
**Metalloproteinase Suppression**
Excavatolide B suppresses expression of matrix metalloproteinase-9 (MMP-9) and cathepsin K in osteoclast differentiation assays at 10 μM, targeting key enzymes responsible for extracellular matrix degradation and bone resorption in arthritic conditions.
**Analgesic Properties**
In vivo carrageenan-induced inflammatory models demonstrate statistically significant analgesic effects compared to untreated controls (p < 0.05), suggesting central or peripheral pain pathway modulation, though the precise analgesic mechanism has not been molecularly defined in published literature.
**COX-2 Protein Inhibition**
At the highest tested concentration of 50 μM, excavatolide B achieves measurable suppression of COX-2 protein expression in murine macrophages, positioning it mechanistically alongside non-steroidal-class anti-inflammatory targets, though selectivity versus COX-1 has not been characterized.
Origin & History
Natural habitat
Excavatolide B is a polyoxygenated diterpenoid isolated from Briareum excavatum, a soft coral (octocoral) belonging to the family Briareidae, distributed across Indo-Pacific and Caribbean reef ecosystems at shallow to moderate depths. The coral inhabits hard substrate reef environments and is not cultivated; all bioactive compound isolation occurs through wild-harvested specimen collection and laboratory extraction. The compound was first characterized in 1998 via solvent extraction and silica gel chromatography fractionation of coral tissue, with NMR spectroscopy confirming structural identity.
“Excavatolide B has no documented history of traditional or ethnopharmacological use in any culture or traditional medicine system; it is a novel synthetic-isolation-era compound first described in scientific literature in 1998. Briareum excavatum coral itself does not appear in any recorded traditional Asian, Pacific Islander, or Caribbean pharmacopeias as a medicinal or nutritional resource, distinguishing it from better-documented marine organisms such as sea cucumbers or certain sponges. The compound's discovery belongs to the broader late-20th-century scientific program of marine natural product chemistry, which systematically surveened reef organisms for bioactive secondary metabolites as leads for pharmaceutical development. Its cultural context is therefore entirely scientific rather than ethnomedical, and its significance lies in its potential as a molecular scaffold for anti-inflammatory drug discovery rather than any heritage of human use.”Traditional Medicine
Scientific Research
The published evidence base for excavatolide B consists exclusively of preclinical research, including in vitro studies using LPS-stimulated RAW 264.7 murine macrophage cell lines (n=6 per group) and in vivo carrageenan-induced rodent inflammation models; no human clinical trials have been registered or completed as of available data. Cell culture studies confirm statistically significant iNOS inhibition at 1–50 μM and COX-2 mRNA inhibition at 25–50 μM (p < 0.05 vs. LPS alone), with COX-2 protein suppression confirmed at 50 μM. Anti-osteoclast activity has been documented at 10 μM in differentiation assays measuring TRAP, MMP-9, cathepsin K, and actin ring formation as endpoints. The overall evidence quality is low by clinical standards—preclinical findings are mechanistically coherent but cannot be extrapolated to human therapeutic use without pharmacokinetic, toxicological, and clinical trial data.
Preparation & Dosage
Traditional preparation
**Laboratory Research Solution**
Dissolved in 0.1% DMSO vehicle for cell culture use; effective concentration range 1–50 μM for anti-inflammatory endpoints in RAW 264.7 macrophages.
**Anti-Osteoclast Research Dose**
10 μM in cell differentiation assays targeting TRAP, MMP-9, and cathepsin K expression.
**Isolation Method**
13 g per extraction batch with >98% purity confirmed by NMR
Extracted from Briareum excavatum tissue via organic solvent extraction followed by normal-phase silica gel column chromatography (n-hexane:ethyl acetate 1:6 gradient elution); yielding approximately 2..
**Commercial / Supplement Forms**
No commercial supplement, pharmaceutical, or standardized extract form exists; not available as a consumer product.
**Human Dose**
No established or recommended human dose; clinical dosing has never been studied.
**Timing / Administration Notes**
Not applicable outside controlled laboratory research settings.
Nutritional Profile
Excavatolide B is a pure isolated diterpenoid compound with molecular formula C₃₁H₄₄O₁₁ and molecular weight 592.6 g/mol; it is not a nutritional ingredient and contributes no macronutrients, micronutrients, calories, vitamins, or minerals. It is classified as a polyoxygenated fusicoccane-type diterpene, a structural class characterized by a complex bicyclic or multicyclic carbon skeleton with multiple oxygen-bearing substituents that confer both bioactivity and lipophilic character. Bioavailability data in any biological system are absent from the published literature; the compound's lipophilicity and high molecular weight suggest potential membrane permeability but also possible solubility limitations in aqueous physiological environments. No phytochemical concentration data exist for the whole coral organism, as excavatolide B is studied exclusively as an isolated pure compound.
How It Works
Mechanism of Action
Excavatolide B inhibits the NF-κB transcription factor pathway in LPS-stimulated macrophages, reducing transcriptional upregulation of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) at both mRNA and protein levels in a dose-dependent manner across 1–50 μM concentrations. Suppression of iNOS decreases nitric oxide (NO) production, which itself serves as a secondary signal sustaining COX-2 expression, creating a dual inhibitory feedback effect on the inflammatory cascade. In osteoclast precursor cells, excavatolide B at 10 μM blocks LPS-induced differentiation by inhibiting actin ring polymerization, TRAP enzymatic activity, MMP-9 secretion, and cathepsin K expression—key effectors of osteoclast-mediated bone resorption. The compound's polyoxygenated diterpenoid scaffold is hypothesized to interact with lipid-soluble regulatory domains given its structural complexity, though direct receptor-binding studies have not yet been published.
Clinical Evidence
No human clinical trials have been conducted for excavatolide B, and it is not approved or regulated as a medicinal or nutritional ingredient in any jurisdiction. All efficacy data originate from in vitro macrophage assays and rodent inflammation models, which demonstrate consistent anti-inflammatory signals but lack translational validation. Effect sizes in cell studies are statistically significant (p < 0.05) for iNOS and COX-2 pathway targets, but clinically meaningful effect magnitudes, therapeutic windows, pharmacokinetics, and safety margins in humans remain entirely undefined. Confidence in any therapeutic claim is therefore very low; excavatolide B is best characterized as an early-stage research compound with plausible mechanisms requiring extensive further investigation before clinical relevance can be assessed.
Safety & Interactions
No formal toxicological studies, adverse event data, drug interaction analyses, or contraindication profiles have been established for excavatolide B in humans or animals; published in vitro studies report no overt cytotoxicity at concentrations up to 50 μM, but this observation has not been systematically validated with dedicated cell viability or apoptosis assays across a broad concentration range. Long-term safety, organ toxicity, genotoxicity, reproductive toxicity, and carcinogenicity are entirely unassessed, making any statement about a safe dose in humans impossible. No information is available regarding interactions with pharmaceutical drugs, including anticoagulants, immunosuppressants, or NSAIDs, although its mechanistic overlap with COX-2 and NF-κB pathways theoretically raises questions about additive effects with existing anti-inflammatory medications. Excavatolide B is not recommended for human consumption, and use during pregnancy or lactation is contraindicated by default given the complete absence of safety data.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Briareum excavatum diterpenoidExcavatolide B (C₃₁H₄₄O₁₁)polyoxygenated fusicoccane diterpeneBriareum excavatum extract bioactive
Frequently Asked Questions
What is excavatolide B and where does it come from?
Excavatolide B is a polyoxygenated diterpenoid compound (C₃₁H₄₄O₁₁, MW 592.6 g/mol) first isolated in 1998 from Briareum excavatum, a soft coral found on Indo-Pacific and Caribbean coral reefs. It is extracted and purified via silica gel chromatography from coral tissue and is studied exclusively as a laboratory research compound, with no commercial supplement form available.
What are the proven anti-inflammatory effects of excavatolide B?
In LPS-stimulated RAW 264.7 murine macrophages, excavatolide B significantly inhibits iNOS mRNA and protein expression at 1–50 μM and COX-2 mRNA at 25–50 μM (p < 0.05 vs. LPS controls, n=6 per group), reducing nitric oxide production through NF-κB pathway suppression. Anti-inflammatory and analgesic effects have also been observed in carrageenan-induced rodent models, though no human clinical trials have been conducted.
Can excavatolide B be used as a supplement for joint pain or arthritis?
Excavatolide B is not available as a supplement and has not been tested in any human clinical trial for joint pain or arthritis. While preclinical data show it inhibits osteoclast differentiation markers including MMP-9, cathepsin K, and TRAP at 10 μM in cell models, these findings have not been translated to human studies, and no safe or effective human dose has been established.
Is excavatolide B safe for human consumption?
There are no human safety data for excavatolide B; no toxicological studies, clinical trials, or adverse event reports have been published. In vitro studies report no overt cytotoxicity at up to 50 μM, but long-term safety, drug interactions, and organ toxicity in humans are completely uncharacterized. Human consumption is not recommended, and use during pregnancy or lactation should be avoided entirely.
How does excavatolide B compare to standard anti-inflammatory drugs like ibuprofen?
Excavatolide B shares a mechanistic target—COX-2 inhibition—with NSAIDs like ibuprofen and celecoxib, but the comparison ends there; ibuprofen has decades of human pharmacokinetic, efficacy, and safety data, while excavatolide B has only preclinical cell and animal data. Its selectivity for COX-2 versus COX-1 has not been studied, and no pharmacokinetic profile in any living system has been published, making direct therapeutic comparison impossible at this stage of research.
What is the optimal dosage range for excavatolide B based on research studies?
Research demonstrates that excavatolide B shows dose-dependent anti-inflammatory effects at concentrations ranging from 1–50 μM in cell studies, with significant COX-2 and iNOS inhibition occurring at 25–50 μM. However, human clinical dosage recommendations have not been firmly established, as most evidence comes from in vitro macrophage models rather than human trials. Anyone considering excavatolide B supplementation should consult a healthcare provider to determine appropriate dosing, as translation from laboratory concentrations to oral supplemental doses requires additional human safety and efficacy data.
Does excavatolide B interact with NSAIDs or other pain management medications?
While excavatolide B and NSAIDs like ibuprofen both inhibit inflammatory pathways (COX-2 and iNOS), there is currently no published research documenting direct drug interactions between excavatolide B and conventional pain medications. Combining excavatolide B with NSAIDs or other medications could theoretically increase anti-inflammatory effects but also potential gastrointestinal or other adverse effects. It is essential to inform your healthcare provider if you are taking excavatolide B alongside any medications, particularly anticoagulants, antiplatelet agents, or other anti-inflammatory compounds.
What does the current clinical evidence tell us about excavatolide B's effectiveness in humans?
Most evidence for excavatolide B comes from laboratory studies using LPS-activated macrophages, which demonstrate significant dose-dependent suppression of inflammatory markers (p < 0.05), but human clinical trials remain limited or absent. This means that while the compound shows promise in reducing nitric oxide and inflammatory signaling at the cellular level, its real-world efficacy and safety in human populations have not been definitively proven. Additional well-designed human studies are needed before excavatolide B can be considered an evidence-based supplement for conditions like arthritis or chronic inflammation.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w excavatolide-b-briareum-excavatum curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
